연구성과로 돌아가기

2021 연구성과 (78 / 281)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
WoS SCOPUS Document Type Document Title Abstract Authors Affiliation ResearcherID (WoS) AuthorsID (SCOPUS) Author Email(s) Journal Name JCR Abbreviation ISSN eISSN Volume Issue WoS Edition WoS Category JCR Year IF JCR (%) FWCI FWCI Update Date WoS Citation SCOPUS Citation Keywords (WoS) KeywordsPlus (WoS) Keywords (SCOPUS) KeywordsPlus (SCOPUS) Language Publication Stage Publication Year Publication Date DOI JCR Link DOI Link WOS Link SCOPUS Link
Article Effects of tofu whey powder on the quality attributes, isoflavones composition and antioxidant activity of wheat flour pan bread Tofu whey, as the liquid by-product of tofu manufacturing, contain a high content of valuable nutrients. While, few studies have focused on the potential use of tofu whey as food ingredient. The study was aimed to evaluate effects of tofu whey powder (TWP) supplementation on physicochemical and functional properties of wheat flour pan bread. TWP-added breads showed significant decrease in baking loss but increase in specific volume, anti-oxidant activities, total phenolic and flavonoid contents of bread samples when increasing the addition levels of TWP. Isoflavone composition analysis showed genistein, daidzein, and glycitein as three major isoflavones, which indicated that the transformation of isoflavone glucosidic conjugates to aglycones was occurred during the bread making. While, at 4% or above addition levels, bread quality was negatively affected by TWP regarding both texture, color profiles and overall acceptance. As a by-product, TWP showed significant potential to improve the bread physicochemical and functional properties. Zhao, Chang-Cheng; Lu, Ji-Ke; Ameer, Kashif Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Henan, Peoples R China; Kyungpook Natl Univ, Sch Food Sci & Biotechnol, Daegu 41566, South Korea ; Ameer, Kashif/H-5449-2019; Lu, Jike/ACM-0432-2022 57224895840; 55752906800; 57190066397 zhaocc91@163.com;kashifameer89@gmail.com; LWT-FOOD SCIENCE AND TECHNOLOGY LWT-FOOD SCI TECHNOL 0023-6438 1096-1127 143 SCIE FOOD SCIENCE & TECHNOLOGY 2021 6.056 19.8 1.67 2025-07-30 20 24 Tofu whey; Bread; Physicochemical properties; Isoflavone composition analysis; Sensory evaluation Bread; Isoflavone composition analysis; Physicochemical properties; Sensory evaluation; Tofu whey Antioxidants; Dairies; Flavonoids; Food products; Physicochemical properties; Textures; Anti-oxidant activities; Bread quality; Color profiles; Composition analysis; Flavonoid content; Food ingredients; Functional properties; Quality attributes; Bakeries English 2021 2021-05 10.1016/j.lwt.2021.111166 바로가기 바로가기 바로가기 바로가기
Article Enhanced production of γ-aminobutyric acid (GABA) using Lactobacillus plantarum EJ2014 with simple medium composition gamma-Aminobutyric acid (GABA) is an amino acid not present in proteins. GABA participates in a variety of physiological functions and has received significant attention in the medical and food industries. In this study, GABA production was investigated using Lactobacillus plantarum. We designed a synthetic medium consisting of the simplest medium components such as yeast extract (nitrogen source), glucose (carbon source), and monosodium L-glutamate (MSG; substrate for GABA) and optimized their proportions to efficiently produce GABA. As a result, 19.8 g/L GABA was obtained under an optimal synthetic medium composition of 100 g/L yeast extract, 10 g/L glucose, and 2.25% MSG, which is the highest among previous studies using L. plantarum. Interestingly, 159.7% of theoretical maximum yield based on initial MSG content was obtained since yeast extract acts as a secondary source of substrate. By proper optimization with the simplest medium using L. plantarum, it can produce a high titer of GABA as well as might help various functional foods containing GABA to develop. Park, Su Jeong; Kim, Dong Hyun; Kang, Hye Jee; Shin, Minhye; Yang, Soo-Yeon; Yang, Jungwoo; Jung, Young Hoon Kyungpook Natl Univ, Sch Food Sci & Biotechnol, Daegu 41566, South Korea; Korea Univ, Grad Sch, Dept Biotechnol, Seoul 02841, South Korea; Seoul Natl Univ, Res Inst Agr & Life Sci, Dept Agr Biotechnol, Seoul 08826, South Korea; Ildong Biosci, 17 Poseunggongdan Ro, Pyeongtaek Si 17957, Gyeonggi Do, South Korea; Kyungpook Natl Univ, Inst Fermentat Biotechnol, Daegu 41566, South Korea ; Kim, Dong Hyun/LDT-2672-2024; Jung, Young/F-1703-2013 57455501200; 55574224522; 57219656318; 57208401604; 57219223890; 56076383700; 55550063700 younghoonjung@knu.ac.kr; LWT-FOOD SCIENCE AND TECHNOLOGY LWT-FOOD SCI TECHNOL 0023-6438 1096-1127 137 SCIE FOOD SCIENCE & TECHNOLOGY 2021 6.056 19.8 4.57 2025-07-30 63 66 gamma-Aminobutyric acid; Lactobacillus plantarum; Glutamate decarboxylase; Monosodium L-glutamate; Yeast extract; Media optimization GLUTAMATE-DECARBOXYLASE; FERMENTATION; BACTERIA; BREVIS; OPTIMIZATION Glutamate decarboxylase; Lactobacillus plantarum; Media optimization; Monosodium L-glutamate; Yeast extract; γ-Aminobutyric acid Amino acids; Bacilli; Glucose; Gamma-aminobutyric acids; Lactobacillus plantarum; Medium components; Medium composition; Nitrogen sources; Physiological functions; Secondary sources; Synthetic medium; Yeast English 2021 2021-02 10.1016/j.lwt.2020.110443 바로가기 바로가기 바로가기 바로가기
Article High-throughput sequencing of the microbial community associated with the physicochemical properties of meju (dried fermented soybean) and doenjang (traditional Korean fermented soybean paste) Doenjang, a traditional Korean soybean paste consisting of fermented meju has been consumed for centuries as a protein source. In this study, the physicochemical factors and microbial communities of samples prepared from four batches of meju and doenjang were investigated to identify the factors that affect the food quality. The water content and salt concentration were higher in doenjang than in meju, and the acidity and amino-type nitrogen varied depending on the batch. After fermentation of doenjang, the pH, salt concentration, and amino-type nitrogen increased in all batches. Enterococcus and Bacillus were present in all meju samples, whereas Enterococcus, Tetragenococcus, and Bacillus were present in all doenjang samples. The dominant fungi in meju and doenjang was Aspergillus. The abundance of certain fungi, such as Debaryomyces, Candida, Mucor, and Gibberella, varied batch to batch. The amino-type nitrogen, which determines the quality of doenjang, was correlated with the relative abundance of Aspergillus in doenjang prior to fermentation. In addition, these strains had a negative correlation with the salt concentration. This study has elucidated the composition of microbial communities in meju and doenjang, which may lead to improved quality in the production of fermented food. Ryu, Jung-A; Kim, Eiseul; Yang, Seung-Min; Lee, Shinyoung; Yoon, Sung-Ran; Jang, Kil-Su; Kim, Hae-Yeong Gyeongsangbuk Do Agr Res & Extens Serv, Daegu 41404, South Korea; Kyungpook Natl Univ, Dept Hort, Daegu 41566, South Korea; Kyung Hee Univ, Inst Life Sci & Resources, Yongin 17104, South Korea; Kyung Hee Univ, Dept Food Sci & Biotechnol, Yongin 17104, South Korea Kim, Hae-Yeong/S-1685-2017 57216744726; 56160562000; 57199267822; 57200426356; 24400410500; 56549474200; 7410133624 hykim@khu.ac.kr; LWT-FOOD SCIENCE AND TECHNOLOGY LWT-FOOD SCI TECHNOL 0023-6438 1096-1127 146 SCIE FOOD SCIENCE & TECHNOLOGY 2021 6.056 19.8 2.89 2025-07-30 43 46 Doenjang; Meju; Physicochemical factor; High-throughput sequencing; Microbial community BACTERIAL DIVERSITY; SOY-SAUCE; SUCCESSION; COMPONENTS; DYNAMICS Doenjang; High-throughput sequencing; Meju; Microbial community; Physicochemical factor Aspergillus; Bacteriology; Fermentation; Nitrogen; Physicochemical properties; Doenjang; Fermented soybeans; Food quality; High-throughput sequencing; Meju; Microbial communities; Physico-chemical factors; Physicochemical property; Protein sources; Salt concentration; Microorganisms English 2021 2021-07 10.1016/j.lwt.2021.111473 바로가기 바로가기 바로가기 바로가기
Article Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab Background ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated with >= 2 chemotherapy regimens. However, its long-term efficacy and outcome of treatment beyond progression (TBP) with nivolumab have not been clarified. Methods The 3-year follow-up data were collected. A subset analysis was performed to explore the efficacy of TBP by assessing postprogression survival (PPS) after the first event of disease progression. Results Overall, 493 patients were randomized (2:1) to receive nivolumab (n = 330) or placebo (n = 163). With a median follow-up of 38.5 (range 36.1-47.5) months, OS of the nivolumab group was significantly longer compared to the placebo group (median 5.3 vs 4.1 months; 3-year survival rate, 5.6% vs 1.9%; hazard ratio [HR], 0.62 [95% confidence interval (CI) 0.50-0.75], P < 0.0001). The median OS of responders (n = 32) who achieved complete response or partial response was 26.7 months and the 3-year survival rate was 35.5% in the nivolumab group. Overall, 109 patients in the nivolumab group and 37 patients in the placebo group received TBP. PPS tended to be longer in the nivolumab group vs placebo group (median 5.8 vs 4.5 months; HR [95% CI], 0.69 [0.47-1.01], P = 0.057). In contrast, PPS was similar between both treatment groups in non-TBP patients (median 2.3 vs 2.2 months; HR 0.90, P = 0.42). Conclusions Long-term efficacy of nivolumab was confirmed at the 3-year follow-up, and a survival benefit of TBP with nivolumab was suggested. Biomarkers for selecting patients suitable for TBP with nivolumab should be identified in the future. Boku, Narikazu; Satoh, Taroh; Ryu, Min-Hee; Chao, Yee; Kato, Ken; Chung, Hyun Cheol; Chen, Jen-Shi; Muro, Kei; Kang, Won Ki; Yeh, Kun-Huei; Yoshikawa, Takaki; Oh, Sang Cheul; Bai, Li-Yuan; Tamura, Takao; Lee, Keun-Wook; Hamamoto, Yasuo; Kim, Jong Gwang; Chin, Keisho; Oh, Do-Youn; Minashi, Keiko; Cho, Jae Yong; Tsuda, Masahiro; Nishiyama, Taihei; Chen, Li-Tzong; Kang, Yoon-Koo Natl Canc Ctr, Div Gastrointestinal Med Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan; Osaka Univ, Grad Sch Med, Frontier Sci Canc & Chemotherapy, Suita, Osaka, Japan; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea; Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan; Yonsei Univ, Yonsei Univ Hlth Syst, Song Dang Inst Canc Res, Div Med Oncol,Yonsei Canc Ctr,Coll Med, Seoul, South Korea; Chang Gung Univ, Linkou Chang Gung Mem Hosp, Dept Internal Med, Div Hematol & Oncol, Taoyuan, Taiwan; Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea; Natl Taiwan Univ Canc Ctr, Dept Med Oncol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Canc Res Ctr, Taipei, Taiwan; Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Kanagawa, Japan; Natl Canc Ctr, Dept Gastr Surg, Tokyo, Japan; Korea Univ, Coll Med, Dept Internal Med, Div Hematol & Oncol, Seoul, South Korea; China Med Univ, China Med Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Taichung, Taiwan; Kindai Univ, Dept Med Oncol, Fac Med, Osakasayama, Japan; Kindai Univ, Nara Hosp, Dept Med Oncol, Ikoma, Japan; Seoul Natl Univ, Bundang Hosp, Coll Med, Div Hematol & Oncol,Dept Internal Med, Seongnam, South Korea; Keio Univ, Sch Med, Keio Canc Ctr, Tokyo, Japan; Kyungpook Natl Univ, Sch Med, Daegu, South Korea; Canc Inst Hosp, Japanese Fdn Canc Res, Dept Gastroenterol, Tokyo, Japan; Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Dept Internal Med,Coll Med, Seoul, South Korea; Chiba Canc Ctr, Clin Trial Promot Dept, Chiba, Japan; Yonsei Univ, Gangnam Severance Hosp, Coll Med, Dept Med Oncol, Seoul, South Korea; Hyogo Canc Ctr, Dept Gastroenterol Oncol, Akashi, Hyogo, Japan; Ono Pharmaceut Co Ltd, Med Affairs, Med Informat, Osaka, Japan; Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Tainan, Taiwan; Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan Chen, Jen-Shi/GLV-3349-2022; Yeh, Kun-Huei/HGD-3316-2022; Satoh, Taroh/AAF-5193-2021; Kang, Yoon-Koo/ABL-4264-2022; Hamamoto, Yasuo/AAA-9941-2022; Yoshikawa, Takaki/Y-1580-2019; Chung, Hyun Cheol/AFB-8969-2022 55359026700; 12040860900; 7101754860; 7402865850; 56502463000; 7404006815; 35075804900; 7006195808; 7202402198; 7201438906; 7402718437; 55647062500; 7201957490; 7403453308; 35205887300; 7103060946; 59501049300; 7202995470; 8836932000; 6506466850; 36805119200; 56012668900; 58438608700; 7409440415; 7402784198 nboku@ncc.go.jp; GASTRIC CANCER GASTRIC CANCER 1436-3291 1436-3305 24 4 SCIE GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY 2021 7.701 19.8 5.96 2025-07-30 82 87 ATTRACTION-2; Gastric or gastroesophageal junction cancer; Nivolumab; Long-term efficacy; Treatment beyond progression ATTRACTION-2; Gastric or gastroesophageal junction cancer; Long-term efficacy; Nivolumab; Treatment beyond progression Adult; Aged; Antineoplastic Agents, Immunological; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nivolumab; Progression-Free Survival; Stomach Neoplasms; Survival Rate; Treatment Outcome; biological marker; nivolumab; placebo; immunological antineoplastic agent; nivolumab; acute hepatitis; adenocarcinoma; adult; Article; chemotherapy; colitis; computer assisted tomography; controlled study; disease exacerbation; double blind procedure; drug efficacy; drug safety; drug therapy; female; follow up; gene mutation; hazard ratio; histology; human; human tissue; hyperthyroidism; image analysis; maculopapular rash; major clinical study; male; microsatellite instability; middle aged; multiple cycle treatment; nuclear magnetic resonance imaging; phase 3 clinical trial; pneumonia; randomized controlled trial; solid malignant neoplasm; stomach cancer; survival rate; thyroiditis; toxicity; tumor cell; tumor volume; aged; clinical trial; mortality; stomach tumor; treatment outcome English 2021 2021-07 10.1007/s10120-021-01173-w 바로가기 바로가기 바로가기 바로가기
Article Risk factors of lymph node metastasis after non-curative endoscopic resection of undifferentiated-type early gastric cancer Background This study aimed to investigate risk factors for lymph node (LN) or distant metastasis after non-curative endoscopic resection (ER) of undifferentiated-type early gastric cancer (EGC). Methods Of 1124 patients who underwent ER for undifferentiated-type gastric cancer at 18 tertiary hospitals across six geographic areas in Korea between 2005 and 2014, 634 with non-curative ER beyond the expanded criteria were retrospectively enrolled. According to the treatment after ER, patients were divided into additional surgery (n = 270) and follow-up (n = 364) groups. The median follow-up duration was 59 months for recurrence and 84 months for mortality. Results LN metastasis was found in 6.7% (18/270) of patients at surgery. Ulcer [odds ratio (OR) 3.83; 95% confidence interval (CI) 1.21-12.13; p=0.022] and submucosal invasion (OR 10.35; 95% CI 1.35-79.48; p=0.025) were independent risk factors. In the follow-up group, seven patients (1.9%) developed LN or distant recurrence. Ulcer [hazard ratio (HR) 7.60; 95% CI 1.39-35.74; p = 0.018], LVI (HR 6.80; 95% CI 1.07-42.99; p = 0.042), and positive vertical margin (HR 6.71; 95% CI 1.28-35.19; p = 0.024) were independent risk factors. In the overall cohort, LN metastasis rates were 9.6% in patients with two or more risk factors and 1.2% in those with no or one risk factor. Conclusions LVI, ulcer, submucosal invasion, and positive vertical margin are independently associated with LN or distant metastasis after non-curative ER of undifferentiated-type EGC. Surgical resection is strongly recommended for patients with two or more risk factors. Yang, Hyo-Joon; Jang, Jae-Young; Kim, Sang Gyun; Ahn, Ji Yong; Nam, Su Youn; Kim, Jie-Hyun; Min, Byung-Hoon; Lee, Wan-Sik; Lee, Bong Eun; Joo, Moon Kyung; Park, Jae Myung; Shin, Woon Geon; Lee, Hang Lak; Gweon, Tae-Geun; Park, Moo In; Choi, Jeongmin; Tae, Chung Hyun; Kim, Young-Il; Choi, Il Ju Sungkyunkwan Univ, Sch Med, Div Gastroenterol, Dept Internal Med,Kangbuk Samsung Hosp, Seoul, South Korea; Sungkyunkwan Univ, Sch Med, Gastrointestinal Canc Ctr, Kangbuk Samsung Hosp, Seoul, South Korea; Kyung Hee Univ, Coll Med, Dept Internal Med, 23 Kyungheedae Ro, Seoul 02447, South Korea; Seoul Natl Univ, Coll Med, Div Gastroenterol, Dept Internal Med, 103 Daehak Ro, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Liver Res Inst, 103 Daehak Ro, Seoul 110744, South Korea; Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Gastroenterol,Coll Med, Seoul, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Gastroenterol, Daegu, South Korea; Yonsei Univ, Gangnam Severance Hosp, Dept Internal Med, Div Gastroenterol,Coll Med, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea; Chonnam Natl Univ, Dept Internal Med, Med Sch, Gwangju, South Korea; Pusan Natl Univ, Dept Internal Med, Sch Med, Busan, South Korea; Korea Univ, Coll Med, Dept Internal Med, Guro Hosp, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Seoul, South Korea; Hallym Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Hanyang Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Seoul, South Korea; Catholic Univ Korea, Div Gastroenterol, Dept Internal Med, Coll Med,Incheon St Marys Hosp, Incheon, South Korea; Kosin Univ, Dept Internal Med, Coll Med, Busan, South Korea; Inje Univ, Sanggye Paik Hosp, Dept Internal Med, Coll Med, Seoul, South Korea; Ewha Womans Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Natl Canc Ctr, Ctr Gastr Canc, Goyang, South Korea Park, Jae Myung/AGK-6655-2022; Kim, Jie-Hyun/Q-9061-2019; Kim, Yuriy/ABD-7016-2020; Kim, Sang/J-5398-2012; Lee, In/J-9324-2013; Ahn, Ji Yong/AGO-1695-2022 57188930761; 57215881098; 56371524600; 36809017800; 55617028500; 49461401400; 7202932034; 57208140974; 36461131900; 35313509000; 8548758100; 13606883400; 7501478057; 55365094900; 8666034000; 55646404000; 35211966400; 57203809495; 7401471464 jyjang@khu.ac.kr;harley1333@hanmail.net; GASTRIC CANCER GASTRIC CANCER 1436-3291 1436-3305 24 1 SCIE GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY 2021 7.701 19.8 1.49 2025-07-30 24 22 Stomach neoplasms; Undifferentiated-type histology; Non-curative resection; Lymph node Metastasis; Risk factors POORLY DIFFERENTIATED ADENOCARCINOMA; SUBMUCOSAL DISSECTION; PREDICTIVE FACTORS; FEASIBILITY; OUTCOMES; SURGERY Lymph node Metastasis; Non-curative resection; Risk factors; Stomach neoplasms; Undifferentiated-type histology Aged; Endoscopic Mucosal Resection; Female; Gastrectomy; Gastric Mucosa; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Postoperative Period; Republic of Korea; Retrospective Studies; Risk Factors; Stomach Neoplasms; adult; Article; cancer mortality; cancer patient; cancer recurrence; cohort analysis; confidence interval; controlled study; distant metastasis; early cancer; endoscopic surgery; female; follow up; hazard ratio; human; lymph node metastasis; major clinical study; male; odds ratio; priority journal; retrospective study; risk assessment; risk factor; South Korea; stomach cancer; surgical margin; tertiary care center; tumor invasion; undifferentiated type early gastric cancer; aged; endoscopic mucosal resection; etiology; gastrectomy; lymph node; lymph node metastasis; middle aged; mortality; pathology; postoperative period; risk factor; stomach mucosa; stomach tumor; tumor recurrence English 2021 2021-01 10.1007/s10120-020-01103-2 바로가기 바로가기 바로가기 바로가기
Article Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol-sorafenib hybrids Sorafenib is recommended as the primary therapeutic drug for patients with hepatocellular carcinoma. To discover a new compound that avoids low response rates and toxic side effects that occur in sorafenib therapy, we designed and synthesized new hybrid compounds of sorafenib and 2,4,5-trimethylpyridin-3-ols. Compound 6 was selected as the best of 24 hybrids that inhibit each of the four Raf kinases. The anti-proliferative activity of 6 in HepG2, Hep3B, and Huh7 cell lines was slightly lower than that of sorafenib. However, in H6c7 and CCD841 normal epithelial cell lines, the cytotoxicity of 6 was much lower than that of sorafenib. In addition, similar to sorafenib, compound 6 inhibited spheroid forming ability of Hep3B cells in vitro and tumour growth in a xenograft tumour model of the chick chorioallantoic membrane implanted with Huh7 cells. Compound 6 may be a promising candidate targeting hepatocellular carcinoma with low toxic side effects on normal cells. Awasthi, Bhuwan Prasad; Chaudhary, Prakash; Guragain, Diwakar; Jee, Jun-Goo; Kim, Jung-Ae; Jeong, Byeong-Seon Yeungnam Univ, Coll Pharm, Gyongsan 38541, South Korea; Kyungpook Natl Univ, Coll Pharm, Daegu 41566, South Korea ; Awasthi, Bhuwan Prasad/MAH-8562-2025; Guragain, Diwakar/AGN-8960-2022 57222337395; 57203412971; 57216684580; 7004327823; 7601363878; 34975054400 jjee@knu.ac.kr;jakim@yu.ac.kr;jeongb@ynu.ac.kr; JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY J ENZYM INHIB MED CH 1475-6366 1475-6374 36 1 SCIE BIOCHEMISTRY & MOLECULAR BIOLOGY;CHEMISTRY, MEDICINAL 2021 5.756 19.8 0.09 2025-07-30 2 2 Molecular hybridisation; Raf kinase; hepatocellular carcinoma; tumour spheroid formation; antitumour activity RAF/MEK/ERK PATHWAY; RAF KINASES; CANCER; BRAF; DISCOVERY; DESIGN; CELLS; 6-AMINO-2,4,5-TRIMETHYLPYRIDIN-3-OLS; ANGIOGENESIS; INHIBITION antitumour activity; hepatocellular carcinoma; Molecular hybridisation; Raf kinase; tumour spheroid formation Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Xenograft Model Antitumor Assays; 2-aminopyrimidine; antineoplastic agent; protein kinase inhibitor; pyrimidine derivative; sorafenib; animal; cell line; cell proliferation; chemistry; chick embryo; drug effect; drug screening; human; liver cell carcinoma; liver tumor; molecular docking; pathology; tumor cell line English 2021 2021-01-01 10.1080/14756366.2021.1953997 바로가기 바로가기 바로가기 바로가기
Article Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial Background/Aims: Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus. Our previous 48-week trial revealed that BSV has comparable antiviral efficacy to tenofovir disoproxil fumarate (TDF) and better safety profiles in terms of improved renal and bone safety. This extension study evaluated the prolonged efficacy and safety of BSV in treatment-naive chronic hepatitis B patients. Methods: Patients continued to participate in an open-label BSV study after an initial 48-week double-blind comparison of BSV and TDF treatment. The antiviral efficacy and drug safety was evaluated up to 192 weeks in two groups: patients continuing BSV treatment (BSV-BSV) and patients switching from TDF to BSV after 48 weeks (TDF-BSV). Results: Among 197 patients receiving randomized treatments, 170 (86%) entered the open-label phase and 152 (77%) entered the 192-week extension study. Virological response rates over 192 weeks were 92.50% and 93.06% in the BSV-BSV and TDF-BSV groups, respectively (P=0.90). Hepatitis B envelop antigen seroconversion and alanine aminotransferase normalization rates were similar between the groups (P=0.75 and P=0.36, respectively). There were no drug-resistant mutations to BSV. Bone mineral density and renal function were well preserved in the BSV-BSV group, whereas these initially worsened then recovered after switching therapy in the TDF-BSV group. Conclusions: BSV maintained potent antiviral efficacy after 192 weeks and showed no evidence of drug resistance. BSV was safe, well tolerated, and effective in patients who switched from TDF to BSV. Song, Do Seon; Kim, Won; Ahn, Sang Hoon; Yim, Hyung Joon; Jang, Jae Young; Kweon, Young Oh; Cho, Yong Kyun; Kim, Yoon Jun; Hong, Gun Young; Kim, Dong Joon; Jung, Young Kul; Sohn, Joo Hyun; Lee, Jin-Woo; Park, Sung Jae; Lee, Byung Seok; Kim, Ju Hyun; Kim, Hong Soo; Yoon, Seung Kew; Kim, Moon Young; Lee, Kwan Sik; Lim, Young Suk; Lee, Wan Sik; Yang, Jin Mo; Kim, Kyun-Hwan; Han, Kwang-Hyub; Um, Soon Ho Catholic Univ Korea, Dept Internal Med, St Vincents Hosp, Seoul, South Korea; Seoul Natl Univ, Seoul Metropolitan Govt, Dept Internal Med, Boramae Med Ctr,Coll Med, Seoul, South Korea; Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Korea Univ, Dept Internal Med, Coll Med, 73 Goryeodae Ro, Seoul 02841, South Korea; Soonchunhyang Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Kyungpook Natl Univ, Dept Internal Med, Coll Med, Daegu, South Korea; Sungkyunkwan Univ, Dept Internal Med, Kangbuk Samsung Hosp, Sch Med, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Liver Res Inst, Coll Med, Seoul, South Korea; Kwangju Christian Hosp, Dept Internal Med, Gwangju, South Korea; Hallym Univ, Dept Internal Med, Chunchon, South Korea; Hallym Univ, Ctr Liver & Digest Dis, Chunchon, South Korea; Hanyang Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Inha Univ, Dept Internal Med, Sch Med, Incheon, South Korea; Inje Univ, Paik Hosp, Dept Internal Med, Busan, South Korea; Chungnam Natl Univ, Dept Gastroenterol & Hepatol, Sch Med, Daejeon, South Korea; Gacheon Univ, Dept Internal Med, Coll Med, Incheon, South Korea; Soonchunhyang Univ, Dept Internal Med, Coll Med, Cheonan, South Korea; Catholic Univ Korea, Dept Internal Med, Seoul St Marys Hosp, Seoul, South Korea; Yonsei Univ, Dept Internal Med, Wonju Coll Med, Wonju, South Korea; Univ Ulsan, Dept Gastroenterol, Asan Med Ctr, Coll Med, Seoul, South Korea; Chonnam Natl Univ, Dept Internal Med, Med Sch, Gwangju, South Korea; Sungkyunkwan Univ, Sch Med, Dept Precis Med, Suwon, South Korea; Korea Natl Evidence Based Healthcare Collaboratin, Seoul, South Korea ; Lim, Young-Suk/AFQ-5165-2022; Ahn, Sang Hoon/AFM-2603-2022; Kim, Yong-Tae/HQZ-0240-2023; Lee, Shin-Jae/D-5883-2012; Lee, Hyun Woo/AAH-8473-2020; Kim, Yoon/J-2746-2012; Kim, Won/H-6940-2019; Kim, Hyun/K-7697-2013; SANG-HOON, AHN/AAV-2600-2020 57217514699; 57049716700; 7401989551; 7005664934; 57221679776; 7004694832; 35261851400; 25947520600; 44161264800; 55806065600; 25626113500; 14621705600; 57216961138; 24176295000; 57203247116; 57216524819; 57205055260; 7404036291; 55545239100; 57301655600; 25224923200; 57208140974; 35367583300; 7409326152; 7402963689; 7005044023 umsh@korea.ac.kr; CLINICAL AND MOLECULAR HEPATOLOGY CLIN MOL HEPATOL 2287-2728 2287-285X 27 2 SCIE GASTROENTEROLOGY & HEPATOLOGY 2021 8.337 19.9 0.75 2025-07-30 13 13 Besifovir; Hepatitis B, Chronic; Drug resistance; Bone mineral density; Nephrotoxicity VIRUS-INFECTION; ASIAN PATIENTS; DOUBLE-BLIND; ENTECAVIR; ALAFENAMIDE; LAMIVUDINE; EFFICACY; HBSAG; RISK Besifovir; Bone mineral density; Drug resistance; Hepatitis B, chronic; Nephrotoxicity alanine aminotransferase; antivirus agent; besifovir; besifovir dipivoxil maleate; carnitine; interferon; tenofovir disoproxil; unclassified drug; adult; antiviral activity; antiviral resistance; antiviral susceptibility; antiviral therapy; Article; bioassay; bone density; bone turnover; chronic hepatitis B; continuous infusion; controlled study; DNA sequencing; double blind procedure; drug efficacy; drug safety; drug sensitivity; drug withdrawal; dual energy X ray absorptiometry; enzyme linked immunosorbent assay; evaluation study; female; glomerulus filtration rate; human; lumbar spine; major clinical study; male; nephrotoxicity; phase 3 clinical trial; randomized controlled trial; Southern blotting; sustained virologic response; virus genome English 2021 2021-04 10.3350/cmh.2020.0307 바로가기 바로가기 바로가기 바로가기
Article Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is closely related to gut-microbiome. There is a paucity of research on which strains of gut microbiota affect the progression of NAFLD. This study explored the NAFLD-associated microbiome in humans and the role of Lactobacillus in the progression of NAFLD in mice. Methods: The gut microbiome was analyzed via next-generation sequencing in healthy people (n=37) and NAFLD patients with elevated liver enzymes (n=57). Six-week-old male C57BL/6J mice were separated into six groups (n=10 per group; normal, Western, and four Western diet + strains [10(9) colony-forming units/g for 8 weeks; L. acidophilus, L. fermentum, L. paracasei, and L. plantarum]). Liver/body weight ratio, liver pathology, serum analysis, and metagenomics in the mice were examined. Results: Compared to healthy subjects (1.6 +/- 4.3), NAFLD patients showed an elevated Firmicutes/Bacteroidetes ratio (25.0 +/- 29.0) and a reduced composition of Akkermansia and L. murinus (P<0.05). In the animal experiment, L. acidophilus group was associated with a significant reduction in liver/body weight ratio (5.5 +/- 0.4) compared to the Western group (6.2 +/- 0.6) (P<0.05). L. acidophilus (41.0 +/- 8.6), L. fermentum (44.3 +/- 12.6), and L. plantarum (39.0 +/- 7.6) groups showed decreased cholesterol levels compared to the Western group (85.7 +/- 8.6) (P<0.05). In comparison of steatosis, L. acidophilus (1.9 +/- 0.6), L. plantarum (2.4 +/- 0.7), and L. paracasei (2.0 +/- 0.9) groups showed significant improvement of steatosis compared to the Western group (2.6 +/- 0.5) (P<0.05). Conclusions: Ingestion of Lactobacillus, such as L. acidophilus, L. fermentum, and L. plantarum, ameliorates the progression of nonalcoholic steatosis by lowering cholesterol. The use of Lactobacillus can be considered as a useful strategy for the treatment of NAFLD. Lee, Na Young; Shin, Min Jea; Youn, Gi Soo; Yoon, Sang Jun; Choi, Ye Rin; Kim, Hyeong Seop; Gupta, Haripriya; Han, Sang Hak; Kim, Byoung Kook; Lee, Do Yup; Park, Tae Sik; Sung, Hotaik; Kim, Byung Yong; Suk, Ki Tae Hallym Univ, Inst Liver & Digest Dis, Coll Med, 1 Hallymdaehak Gil, Chunchon 24252, South Korea; Hallym Univ, Dept Pathol, Coll Med, Chunchon, South Korea; Chong Kun Dang Bio Res Inst, Ansan, South Korea; Seoul Natl Univ, Dept Agr Biotechnol, Seoul, South Korea; Gachon Univ, Dept Life Sci, Sungnam, South Korea; Kyungpook Natl Univ, Coll Med, Dept Med, Daegu 41944, South Korea; ChunLab Inc, Dept Microbiome, Seoul, South Korea Gupta, Haripriya/ADF-9486-2022; Kim, Byung-Yong/JLL-7806-2023; Kim, Sukjun/AAV-8503-2021; Lee, Nayoung/LXB-5417-2024 bykim@chunlab.com;ktsuk@hallym.ac.kr; CLINICAL AND MOLECULAR HEPATOLOGY CLIN MOL HEPATOL 2287-2728 2287-285X 27 1 SCIE GASTROENTEROLOGY & HEPATOLOGY 2021 8.337 19.9 101 Nonalcoholic fatty liver disease; Lactobacillus; Probiotics; Gut microbiome; Cholesterol INSULIN-RESISTANCE; GUT MICROBIOTA; PLANTARUM; STEATOHEPATITIS; ACCUMULATION; INFLAMMATION; METABOLISM; PROBIOTICS; FERMENTUM; CIRRHOSIS English 2021 2021-01 10.3350/cmh.2020.0125 바로가기 바로가기 바로가기
Article Left Ventricular Ejection Fraction 1 Year After Acute Myocardial Infarction Identifies the Benefits of the Long-Term Use of β-Blockers Analysis of Data From the KAMIR-NIH Registry BACKGROUND: beta-Blockers can improve prognosis after acute myocardial infarction. However, it remains unclear how long beta-blockers should be prescribed. METHODS: We included patients from the prospective, nationwide Korea Acute Myocardial Infarction Registry-National Institutes of Health registry and collected data on beta-blockers and left ventricular ejection fraction (LVEF) at 1-year follow-up. Patients were stratified into 2 groups: 1001 patients with a 1-year LVEF RESULTS: A total of 3177 patients received beta-blockers at 1 year, and 151 patients died during the 2-year follow-up from 1 year after index hospitalization. beta-Blockers showed survival benefits in patients with a 1-year LVEF= 50% (log-rank P=0.311). After adjusting covariates, beta-blockers were associated with a 51% reduction in mortality in patients with a 1-year LVEF<50% (P=0.020) but not in their counterparts (P=0.322). Indeed, there was a prognostic interaction between the use of beta-blockers at 1 year and 1-year LVEF (P for interaction=0.004). CONCLUSIONS: Use of beta-blockers at 1-year follow-up after acute MI was associated with improved outcomes in patients with an LVEF50% at 1 year. This study provides valuable information about differential responsiveness to beta-blockers according to 1-year LVEF and might suggest the proper duration of beta-blockers after acute MI. REGISTRATION: URL: http://cris.nih.go.kr/cris/en/; Unique identifier: KCT0000863. GRAPHIC ABSTRACT: A graphic abstract is available for this article. Park, Chan Soon; Yang, Han-Mo; Ki, You-Jeong; Kang, Jeehoon; Han, Jung-Kyu; Park, Kyung Woo; Kang, Hyun-Jae; Koo, Bon-Kwon; Kim, Chong-Jin; Cho, Myeong Chan; Kim, Young Jo; Chae, Shung-Chull; Jeong, Myung Ho; Kim, Hyo-Soo Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Kyung Hee Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Chungbuk Natl Univ, Dept Internal Med, Coll Med, Cheongju, South Korea; Yeungnam Univ Hosp, Dept Internal Med, Div Cardiol, Daegu, South Korea; Kyungpook Natl Univ, Dept Internal Med, Coll Med, Daegu, South Korea; Chonnam Natl Univ Hosp, Dept Internal Med, Gwangju, South Korea; Chonnam Natl Univ Hosp, Heart Ctr, Gwangju, South Korea Koo, Bon-Kwon/J-5374-2012; kang, Hyun-Jae/D-6121-2012; Park, Kyung Woo/AAX-3046-2020; Han, Jung-Kyu/JGE-4952-2023; Kim, Jin Sug/AAY-6890-2021; YANG, HANMO/HNB-9532-2023; Kim, Hyo/J-2753-2012; Kang, Hyun-Jae/D-6121-2012 57198830480; 55153939700; 57202030642; 55139508800; 55590483500; 35300576900; 27171630200; 35285769200; 35229511500; 7401727518; 57189907572; 7101962036; 56485157500; 33567809200 hanname@hanmail.net; CIRCULATION-CARDIOVASCULAR INTERVENTIONS CIRC-CARDIOVASC INTE 1941-7640 1941-7632 14 4 SCIE CARDIAC & CARDIOVASCULAR SYSTEMS 2021 7.514 19.9 1.56 2025-07-30 21 23 heart failure; hospitalization; mortality; myocardial infarction; prognosis HEART-FAILURE; MORTALITY; THERAPY; METOPROLOL; DISEASE; KOREA heart failure; hospitalization; mortality; myocardial infarction; prognosis Humans; Myocardial Infarction; Registries; Stroke Volume; Ventricular Function, Left; beta adrenergic receptor blocking agent; acute heart infarction; adult; all cause mortality; Article; clinical outcome; controlled study; drug efficacy; echocardiography; female; follow up; heart left ventricle ejection fraction; hospitalization; human; Korea; long term care; major clinical study; male; middle aged; mortality rate; mortality risk; multicenter study; prognosis; prospective study; risk reduction; survival; heart infarction; heart left ventricle function; heart stroke volume; register English 2021 2021-04 10.1161/circinterventions.120.010159 바로가기 바로가기 바로가기 바로가기
Article Protectin D1 reduces imiquimod-induced psoriasiform skin inflammation Specialized proresolving mediators are enzymatically oxygenated natural molecules derived from polyunsaturated fatty acids and are considered novel. These novel mediators include lipoxins from arachidonic acid, resolvins and protectins from omega-3 essential fatty acids, and new maresins. These mediators harbor potent dual proresolving and anti-inflammatory properties. Resolvins and protectins are known to be potent when administered to various inflammation-associated animal models of human diseases. Although psoriasis' etiology remains unknown, there is accumulating evidence indicating that cytokines, including tumor necrosis factor (TNF)-alpha, interleukin (IL)-23, and IL-17, play pivotal roles in its development. Experimentally, resolvins, maresins, and lipoxins downregulate the cytokine expression of the IL-23/IL-17 axis and inhibition of mitogenactivated protein kinases and nuclear factor kappa-light-chain-enhancer of activated B (NF-KB) cell signaling transduction pathways. Here, we assessed the effects of protectin D1 (PD1) on imiquimod (IMQ)-induced psoriasiform skin inflammation and keratinocytes. PD1 showed clinical improvement in skin thickness, redness, and scaling in psoriasis mouse models. Moreover, PD1 decreased IL-1(i, IL-6, IL-17, and CXCL1 mRNA expressions and reduced STAT1 and NF-KB signaling pathway activation in lesions. Serum myeloperoxidase, IgG2a, IL-1(i, IL 6, IL-17, and TNF-alpha and spleen CD4+IFN-gamma+IL-17+ T lymphocytes were reduced after PD1 treatment in IMQinduced psoriasiform mouse models. In addition, IL-1(i, IL-6, IL-8, and IL-18BP gene expressions were decreased in PD1-treated keratinocytes. Moreover, a decrease in the expression levels of CCL17 and IL-6 and an inhibition of the STAT1 and NF-KB signaling transduction pathways was observed in keratinocytes. These PD1 anti-inflammatory effects suggest that it is a good therapeutic candidate for psoriasis. Park, Kyung-Duck; Kim, Namkyung; Kang, Jinjoo; Dhakal, Hima; Kim, Jun Young; Jang, Yong Hyun; Lee, Weon Ju; Lee, Seok-Jong; Kim, Sang-Hyun Kyungpook Natl Univ, Sch Med, Dept Dermatol, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Pharmacol, CMRI, Daegu, South Korea Lee, Joong/A-5417-2013 55767995700; 57216981866; 57216977823; 57195999763; 35310922800; 57016046400; 24474659000; 56013454400; 57210450420 gdpk1217@knu.ac.kr;shkim72@knu.ac.kr; INTERNATIONAL IMMUNOPHARMACOLOGY INT IMMUNOPHARMACOL 1567-5769 1878-1705 98 SCIE IMMUNOLOGY;PHARMACOLOGY & PHARMACY 2021 5.714 19.9 0.88 2025-07-30 14 16 Proresolving lipid mediator; Protectin D1; Psoriasis NF-KAPPA-B; LIPID MEDIATORS; TNF-ALPHA; RESOLUTION; PATHOGENESIS; CYTOKINES; IL-6 Proresolving lipid mediator; Protectin D1; Psoriasis Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Docosahexaenoic Acids; Female; HaCaT Cells; Humans; Imiquimod; Injections, Subcutaneous; Keratinocytes; Mice; Phosphorylation; Psoriasis; Signal Transduction; Skin; Spleen; STAT1 Transcription Factor; Th1 Cells; Th17 Cells; antiinflammatory agent; antipsoriasis agent; CD4 antigen; CXCL1 chemokine; dexamethasone; G protein coupled receptor; G protein coupled receptor 37; imiquimod; immunoglobulin G2; interleukin 17; interleukin 18 binding protein; interleukin 1beta; interleukin 23; interleukin 6; interleukin 8; messenger RNA; mitogen activated protein kinase; myeloperoxidase; protectin d1; STAT1 protein; thymus and activation regulated chemokine; tumor necrosis factor; unclassified drug; antiinflammatory agent; cytokine; docosahexaenoic acid; imiquimod; protectin D1; STAT1 protein; Stat1 protein, mouse; animal cell; animal experiment; animal model; animal tissue; antiinflammatory activity; Article; controlled study; dose response; down regulation; drug cytotoxicity; female; gene expression; HaCat cell line; human; human cell; imiquimod-induced psoriasis; keratinocyte; low drug dose; mouse; neutrophil; NF kB signaling; nonhuman; protein phosphorylation; skin redness; skinfold thickness; spleen; T lymphocyte; animal; cytology; disease model; drug effect; immunology; metabolism; pathology; phosphorylation; psoriasis; signal transduction; skin; subcutaneous drug administration; Th1 cell; Th17 cell English 2021 2021-09 10.1016/j.intimp.2021.107883 바로가기 바로가기 바로가기 바로가기
Article The dynamic history of gymnosperm plastomes: Insights from structural characterization, comparative analysis, phylogenomics, and time divergence Gymnosperms are among the most endangered groups of plant species; they include ginkgo, pines (Conifers I), cupressophytes (Conifers II), cycads, and gnetophytes. The relationships among the five extant gymnosperm groups remain equivocal. We analyzed 167 available gymnosperm plastomes and investigated their diversity and phylogeny. We found that plastome size, structure, and gene order were highly variable in the five gymnosperm groups, of which Parasitaxus usta (Vieill.) de Laub. and Macrozamia mountperriensis F.M.Bailey had the smallest and largest plastomes, respectively. The inverted repeats (IRs) of the five groupswere shown to have evolved through distinctive evolutionary scenarios. The IRs have been lost in all conifers but retained in cycads and gnetophytes. A positive association between simple sequence repeat (SSR) abundance and plastome size was observed, and the SSRs with the most variation were found in Pinaceae. Furthermore, the number of repeats was negatively correlated with IR length; thus, the highest number of repeats was detected in Conifers I and II, in which the IRs had been lost. We constructed a phylogeny based on 29 shared genes from 167 plastomes. With the plastome tree and 13 calibrations, we estimated the tree height between present-day angiosperms and gymnosperms to be similar to 380 million years ago (mya). The placement of Gnetales in the tree agreed with the Gnetales-other gymnosperms hypothesis. The divergence between Ginkgo and cycads was estimated as similar to 284 mya; the crown age of the cycads was 251 mya. Our time-calibrated plastid-based phylogenomic tree provides a framework for comparative studies of gymnosperm evolution. Lubna; Asaf, Sajjad; Khan, Abdul Latif; Jan, Rahmatullah; Khan, Arif; Khan, Adil; Kim, Kyung-Min; Lee, In-Jung Abdul Wali Khan Univ, Dept Bot, Garden Campus, Mardan 23200, Pakistan; Univ Nizwa, Nat & Med Sci Res Ctr, Nizwa 616, Oman; Univ Houston, Dept Biotechnol, Div Plant Biosci, Coll Technol, Houston, TX 77204 USA; Kyungpook Natl Univ, Coll Agr & Life Sci, Sch Appl Biosci, Div Plant Biosci, Daegu 41566, South Korea; Nord Univ, Fac Biosci & Aquaculture, Genom Grp, N-8049 Bodo, Norway; Texas Tech Univ, Inst Genom Crop Abiot Stress Tolerance, Dept Plant & Soil Sci, Lubbock, TX 79409 USA Lee, In-Jung/GLS-0432-2022; Khan, Adil/AAC-5160-2022; Asaf, Sajjad/ABA-3647-2021; Khan, Abdul/H-5910-2011; Kim, Kyung-Min Kim/C-7007-2014; Jan, Rahmatullah/AIC-3439-2022; khan, Arif/HMV-3165-2023 latifepm78@yahoo.co.uk;ijlee@knu.ac.kr; PLANT GENOME PLANT GENOME-US 1940-3372 14 3 SCIE GENETICS & HEREDITY;PLANT SCIENCES 2021 4.219 19.9 10 COMPLETE CHLOROPLAST GENOME; INVERTED REPEAT COPIES; EVOLUTIONARY SIGNIFICANCE; PLASTID GENOME; GINKGO-BILOBA; GENE-TRANSFER; NDH GENES; SEQUENCE; DNA; PINACEAE English 2021 2021-11 10.1002/tpg2.20130 바로가기 바로가기 바로가기
Article The role of CECR1 in the immune-modulatory effects of butyrate and correlation between ADA2 and M1/M2 chemokines in tuberculous pleural effusion Objectives: The Cat Eye Syndrome Critical Region, Candidate 1 (CECR1) gene encoding adenosine deaminase 2 (ADA2) is mainly expressed by macrophages. Given the immunomodulatory functions of butyrate, we examined the effect of butyrate on CECR1 expression of macrophages and the relationship between ADA2 and M1/M2 macrophages-associated chemokines in pleural fluid of patients with tuberculous pleural effusion (TPE). Methods: Expression of CECR1 was evaluated in lipopolysaccharide (LPS)-stimulated and/or butyrate treated THP-1 cells. The role of CECR1 on butyrate-induced immune response was evaluated using siRNA transfected THP-1 cells. M1/M2 chemokines and ADA2 were measured in pleural fluid of patients with TPE. Results: Butyrate promoted the expression of CECR1 and M2-macrophage markers in THP-1 cells. CECR1 was found to be involved in regulating M2 polarization in THP-1 cells treated with LPS and butyrate. Among chemokines measured in pleural fluid of patients with TPE, there was a significant negative correlation between CCL21 and ADA2 levels and between CCL25 and ADA2 levels, and a significant positive correlation between TGF-beta and ADA2 levels and between IL-22 and ADA2 levels. Conclusions: CECR1 played an important role in the butyrate-modulated inflammatory responses in LPSstimulated THP-1 cells. ADA2 may exert anti-inflammatory effects during the process of pleural inflammation in patients with TPE. Park, Ji Eun; Kim, Ha-Jeong; Choi, Sun Ha; Lee, Yong Hoon; Seo, Hyewon; Yoo, Seung Soo; Lee, Shin Yup; Cha, Seung Ick; Park, Jae Yong; Kim, Chang Ho; Lee, Jaehee Kyungpook Natl Univ, Sch Med, Dept Internal Med, 680 Gukchaebosang Ro, Daegu 41944, South Korea; Kyungpook Natl Univ, Tumor Heterogene & Network THEN Res Ctr, BK21 Plus KNU Biomed Convergence Program, Dept Physiol,Cell & Matrix Res Inst,Sch Med, Daegu, South Korea Choi, Sun Ha/HPD-7234-2023; Lee, Jun Young/CAI-2335-2022; Lee, You/T-6086-2019; Lee, Jaehee/S-1697-2018 57195437358; 57191717512; 57199723585; 57199022948; 55612130200; 56479781600; 49863712700; 35227126400; 58360293800; 7409873555; 13805476000 kimch@knu.ac.kr;jaelee@knu.ac.kr; INTERNATIONAL IMMUNOPHARMACOLOGY INT IMMUNOPHARMACOL 1567-5769 1878-1705 96 SCIE IMMUNOLOGY;PHARMACOLOGY & PHARMACY 2021 5.714 19.9 0.15 2025-07-30 2 2 CECR1; Butyrate; ADA2; M2; Tuberculous pleural effusion ADENOSINE-DEAMINASE 2; MACROPHAGE POLARIZATION; EXPRESSION; MICROBIOTA; ISOENZYMES; MONOCYTES; CELLS ADA2; Butyrate; CECR1; M2; Tuberculous pleural effusion Adenosine Deaminase; Butyrates; Chemokines; Cytokines; Humans; Intercellular Signaling Peptides and Proteins; Lipopolysaccharides; Macrophage Activation; Macrophages; Pleural Effusion; THP-1 Cells; Tuberculosis, Pleural; adenosine deaminase; adenosine deaminase 2; butyric acid; chemokine; gamma interferon inducible protein 10; inducible nitric oxide synthase; interleukin 10; interleukin 1beta; interleukin 2; interleukin 22; messenger RNA; secondary lymphoid tissue chemokine; transforming growth factor beta; tumor necrosis factor; unclassified drug; ADA2 protein, human; adenosine deaminase; butyric acid derivative; chemokine; cytokine; lipopolysaccharide; signal peptide; adult; Article; cat eye syndrome critical region, candidate 1 gene; cell culture; cell differentiation; cell lysate; controlled study; enzyme activity; flow cytometry; gene; human; human cell; immune response; immunomodulation; lung tuberculosis; macrophage; mononuclear cell; mRNA expression level; nonhuman; phenotype; pleura effusion; pleura fluid; polarization; priority journal; protein expression; RNA isolation; THP-1 cell line; tuberculous pleural effusion; drug effect; genetics; immunology; macrophage; macrophage activation; metabolism; pleura effusion; tuberculous pleurisy English 2021 2021-07 10.1016/j.intimp.2021.107635 바로가기 바로가기 바로가기 바로가기
Article Ursolic acid inhibits FceRI-mediated mast cell activation and allergic inflammation Background: Mast cells are the primary cells that play a crucial role in the allergic diseases via secretion of diverse allergic mediators. Ursolic acid (UA) is a naturally occurring anti-inflammatory triterpenoid possessing various biological properties such as immune regulation, antioxidant, and anti-fibrotic. The aim of this study was to evaluate the effects of UA in FceRI-mediated mast cell activation and allergic inflammation. Methods: In this study, mast cells were stimulated with immunoglobulin E (IgE) and the anti-allergic effects of UA were assessed by measuring the levels of allergic mediators. In vivo effects of UA were observed by generating passive cutaneous anaphylaxis (PCA) and active systemic anaphylaxis (ASA) in mouse model. Results: We found that UA inhibited the degranulation of mast cell by suppressing the intracellular calcium level in a concentration-dependent manner. UA inhibited the expression and the release of pro-inflammatory cytokines in mast cells. Anti-allergic effects of UA were demonstrated via suppression of FceRI-mediated signaling mole-cules. In addition, UA inhibited the IgE-mediated PCA and ovalbumin-induced ASA reactions in a dose-dependent manner. Conclusions: Based on these findings, we suggest that UA might have potential as a therapeutic candidate for the treatment of allergic inflammatory diseases via inhibition of FceRI-mediated mast cell activation. Dhakal, Hima; Kim, Min -Jong; Lee, Soyoung; Choi, Young-Ae; Kim, Namkyung; Kwon, Taeg Kyu; Khang, Dongwoo; Kim, Sang-Hyun Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Cell & Matrix Res Inst, Daegu, South Korea; Korea Res Inst Biosci & Biotechnol, Immunoregulatory Mat Res Ctr, Jeongeup, South Korea; Keimyung Univ, Sch Med, Dept Immunol, Daegu, South Korea; Gachon Univ, Sch Med, Dept Physiol, 191 Hambangmoe Ro, Incheon, South Korea 57195999763; 57192888932; 8537269200; 7404777420; 57216981866; 7202206057; 26039177500; 57210450420 dkhang@gachon.ac.kr;shkim72@knu.ac.kr; INTERNATIONAL IMMUNOPHARMACOLOGY INT IMMUNOPHARMACOL 1567-5769 1878-1705 99 SCIE IMMUNOLOGY;PHARMACOLOGY & PHARMACY 2021 5.714 19.9 0.81 2025-07-30 10 11 Mast cell; Ursolic acid; Allergic inflammation; Histamine HISTAMINE-RELEASE; DEGRANULATION; ANAPHYLAXIS; MECHANISMS Allergic inflammation; Histamine; Mast cell; Ursolic acid Anaphylaxis; Animals; Anti-Inflammatory Agents; Calcium; Cell Degranulation; Cytokines; Inflammation; Male; Mast Cell Activation Disorders; Mast Cells; Mice; Mice, Inbred ICR; Rats; Rats, Sprague-Dawley; Signal Transduction; Triterpenes; Ursolic Acid; immunoglobulin E; ovalbumin; ursolic acid; antiinflammatory agent; calcium; cytokine; triterpene; ursolic acid; allergic disease; animal cell; animal experiment; animal model; antiallergic activity; Article; bone marrow derived mast cell; calcium cell level; cell activation; cell viability; chemical structure; chemoluminescence; controlled study; degranulation assay; enzyme linked immunosorbent assay; fluorescence intensity; gene expression; immunodetection; in vitro study; in vivo study; male; mast cell; mast cell degranulation; mouse; MTT assay; nonhuman; passive skin anaphylaxis; peritoneum mast cell; rat; real time polymerase chain reaction; systemic anaphylaxis; anaphylaxis; animal; degranulation; drug effect; inflammation; Institute for Cancer Research mouse; mast cell; mast cell activation disorder; metabolism; signal transduction; Sprague Dawley rat English 2021 2021-10 10.1016/j.intimp.2021.107994 바로가기 바로가기 바로가기 바로가기
Article Effect of Loading Frequency on Volumetric Strain Accumulation and Stiffness Improvement in Sand under Drained Cyclic Direct Simple Shear Tests The effect of the loading frequency on the volumetric strain accumulation, stiffness improvement, and damping ratio of silica sand during cyclic shearing of the silica sand was investigated by performing drained cyclic strain-controlled direct simple shear tests. Cyclic shear strain amplitudes (gamma(c)) of 0.5% and 1.0%; vertical effective stresses (sigma(v0)') of 100, 200, and 300 kPa; and loading frequencies (f) of 0.05, 0.1, 0.5, and 1 Hz were considered. Sand samples were prepared in the loose (Dr=40%) and dense (D-r=80%) states using dry Nakdong River sand. For loose sand tested at sigma v0 '=100 and 200 kPa, the test results showed that the rate of volumetric strain accumulation decreased with increasing f, and the decrease was independent of sigma(v0)' and more obvious at the higher gamma(c) value. The maximum decrease in the volumetric strain accumulation was 60%, which corresponded to a 20-fold increase in f, from 0.05 to 1 Hz. For dense sand tested at sigma(v0)'=300 kPa, the accumulated rate of volumetric strain was essentially identical, especially at gamma(c)=1.0%. The shear modulus ratio always increased with the increase of f for both loose and dense sand, but the difference between shear modulus ratios at different f was reduced with the increase of sigma(v0)', when the samples were sheared at gamma(c)=1.0%. The improvement parameter t, which is proposed in this study and which represents the increase in the rate of cyclic stiffness with the number of cycles (N), increased linearly with f. For loose sand, it increased by approximately 56% and 12% at gamma(c)=0.5% and 1.0%, regardless of sigma(v0)', respectively. The normalized damping ratio (lambda(n)) was independent of D-r, sigma(v0)', f, and gamma(c), and the relationship between lambda(n) and N was well expressed by a power function. The effect of the loading frequency on Nakdong River sand inferred from a drained test was similar to that indicated by an undrained test. (c) 2021 American Society of Civil Engineers. Nong, Zhen-Zhen; Park, Sung-Sik Jiangsu Univ Sci & Technol, Dept Naval Architecture & Ocean Engn, Zhenjiang 212100, Jiangsu, Peoples R China; Jiangsu Prov Engn Res Ctr Geoenvironm Disaster Pr, Zhenjiang 212100, Jiangsu, Peoples R China; Kyungpook Natl Univ, Dept Civil Engn, 1370 Sangyeok Dong, Daegu 702701, South Korea zznong@foxmail.com;sungpark@knu.ac.kr; JOURNAL OF GEOTECHNICAL AND GEOENVIRONMENTAL ENGINEERING J GEOTECH GEOENVIRON 1090-0241 1943-5606 147 12 SCIE ENGINEERING, GEOLOGICAL;GEOSCIENCES, MULTIDISCIPLINARY 2021 4.6 20.1 11 Loading frequency; Volumetric strain accumulation; Shear modulus; Stiffness improvement; Cyclic simple shear test English 2021 2021-12-01 10.1061/(asce)gt.1943-5606.0002706 바로가기 바로가기 바로가기
Article Multi-layered polymer cantilever integrated with full-bridge strain sensor to enhance force sensitivity in cardiac contractility measurement In this study, we developed a multi-layered functional cantilever for real-time force measurement of cardiomyocytes in cell culture media. The functional cantilever with a full-bridge circuit configuration was composed of one polydimethylsiloxane (PDMS) and two polyimide (PI) layers, forming two resistive sensors on each upper side of the two PI layers. The PI layers were chemically bonded using an oxygen plasma treatment, with a thin composite layer consisting of Cr/SiO2/PDMS. These greatly improved the force sensitivity and the long-term reliability of the integrated strain sensor operating in liquids. The nanogrooved PDMS top layer bonded on the upper PI layer was employed to further improve the growth of cardiomyocytes on the functional cantilever. The difference in resistance changes and response characteristics was confirmed by evaluating the characteristics of the multi-layered polymer cantilevers with half-bridge and full-bridge circuit configurations. We also employed the cantilever devices to measure the contraction force of cardiomyocytes for 16 days and side effects in real time in human-induced pluripotent stem cells treated with the cardiovascular drug verapamil. The sensor-integrated cantilever devices are expected to be utilized as a novel biomedical sensor for evaluating the mechanobiology of cardiomyocytes, as well as in drug screening tests. Kim, Dong-Su; Jeong, Yun-Jin; Park, Jongsung; Shanmugasundaram, Arunkumar; Lee, Dong-Weon Chonnam Natl Univ, Sch Mech Engn, Gwangju 61186, South Korea; Kyungpook Natl Univ, Dept Precis Mech Engn, Sangju 37224, Gyeongsangbuk D, South Korea; Chonnam Natl Univ, Ctr Next Generat Sensor Res & Dev, Gwangju 61186, South Korea; Chonnam Natl Univ, Adv Med Device Res Ctr Cardiovasc Dis, Gwangju 61186, South Korea Shanmugasundaram, Dr. Arunkumar/ABD-4029-2020; 김, 동수/IAN-1770-2023; SHANMUGASUNDARAM, ARUNKUMAR/ABD-4029-2020 56569118200; 56261982700; 57189583605; 55750828400; 34875377700 mems@jnu.ac.kr; ANALYST ANALYST 0003-2654 1364-5528 146 23 SCIE CHEMISTRY, ANALYTICAL 2021 5.227 20.1 0.51 2025-07-30 7 8 MICROPHYSIOLOGICAL DEVICES Humans; Mechanical Phenomena; Myocardial Contraction; Polymers; Reproducibility of Results; Silicon Dioxide; Biosensors; Bridge circuits; Cell culture; Microchannels; Nanocantilevers; Plasma applications; Silicones; Stem cells; polymer; silicon dioxide; Cardiomyocytes; Circuit configurations; Force sensitivity; Full bridge; Layered polymers; Multi-layered; Polyimide layers; Polymer cantilevers; Real- time; Strain sensors; heart contraction; human; mechanics; reproducibility; Polydimethylsiloxane English 2021 2021-11-22 10.1039/d1an01208h 바로가기 바로가기 바로가기 바로가기
페이지 이동:

논문 데이터 용어 설명

용어 설명
WoS Web of Science. Clarivate Analytics에서 제공하는 학술 데이터베이스입니다. 해당 논문이 WoS에 수록되어 있는지 여부를 표시합니다 (○: 수록됨).
SCOPUS Elsevier에서 제공하는 세계 최대 규모의 초록 및 인용 데이터베이스입니다. 해당 논문이 SCOPUS에 수록되어 있는지 여부를 표시합니다 (○: 수록됨).
Document Type 문헌의 유형을 나타냅니다. Article(원저), Review(리뷰), Proceeding Paper(학회논문), Editorial Material(편집자료), Letter(레터) 등으로 분류됩니다.
Title 논문의 제목입니다.
Abstract 논문의 초록(요약)입니다. 연구의 목적, 방법, 결과, 결론을 간략히 요약한 내용입니다.
Authors 논문의 저자 목록입니다. 공동 저자가 여러 명인 경우 세미콜론(;)으로 구분됩니다.
Affiliation 저자들의 소속 기관 정보입니다. 대학, 연구소, 기업 등 저자가 소속된 기관명이 표시됩니다.
ResearcherID (WoS) Web of Science의 고유 연구자 식별번호입니다. 동명이인을 구분하고 연구자의 업적을 정확하게 추적할 수 있습니다.
AuthorsID (SCOPUS) SCOPUS의 고유 저자 식별번호입니다. 연구자의 모든 출판물을 추적하고 관리하는 데 사용됩니다.
Journal 논문이 게재된 학술지의 정식 명칭입니다.
JCR Abbreviation Journal Citation Reports에서 사용하는 저널의 공식 약어입니다. 저널을 간략하게 표기할 때 사용됩니다.
ISSN International Standard Serial Number. 국제표준연속간행물번호로, 인쇄본 저널에 부여되는 고유 식별번호입니다.
eISSN Electronic ISSN. 전자 버전 저널에 부여되는 고유 식별번호입니다.
Volume 저널의 권(Volume) 번호입니다. 보통 연도별로 하나의 권이 부여됩니다.
Issue 저널의 호(Issue) 번호입니다. 한 권 내에서 여러 호로 나누어 출판되는 경우가 많습니다.
WoS Edition Web of Science의 에디션입니다. SCIE(Science Citation Index Expanded), SSCI(Social Sciences Citation Index), AHCI(Arts & Humanities Citation Index) 등으로 구분됩니다.
WoS Category Web of Science의 주제 분류 카테고리입니다. 저널과 논문이 속한 학문 분야를 나타냅니다.
JCR Year 해당 저널의 JCR(Journal Citation Reports) 지표가 산출된 연도입니다.
IF (Impact Factor) 저널 영향력 지수. 최근 2년간 발표된 논문이 해당 연도에 평균적으로 인용된 횟수를 나타냅니다. 저널의 학술적 영향력을 나타내는 대표적인 지표입니다.
JCR (%) 해당 카테고리에서 저널이 위치하는 상위 백분율입니다. 값이 낮을수록 우수한 저널임을 의미합니다 (예: 5%는 상위 5%를 의미).
FWCI Field-Weighted Citation Impact. 분야별 가중 인용 영향력 지수입니다. 논문이 받은 인용을 동일 분야, 동일 연도, 동일 문헌 유형의 평균과 비교한 값입니다. 1.0이 평균이며, 1.0보다 높으면 평균 이상의 인용을 받았음을 의미합니다.
FWCI UpdateDate FWCI 값이 마지막으로 업데이트된 날짜입니다. FWCI는 인용이 누적됨에 따라 주기적으로 업데이트됩니다.
WOS Citation Web of Science에서 집계된 해당 논문의 총 인용 횟수입니다.
SCOPUS Citation SCOPUS에서 집계된 해당 논문의 총 인용 횟수입니다.
Keywords (WoS) 저자가 논문에서 직접 지정한 키워드입니다. Web of Science에 등록된 저자 키워드 목록입니다.
KeywordsPlus (WoS) Web of Science에서 자동으로 추출한 추가 키워드입니다. 논문의 참고문헌 제목에서 자주 등장하는 단어들로 생성됩니다.
Keywords (SCOPUS) 저자가 논문에서 직접 지정한 키워드입니다. SCOPUS에 등록된 저자 키워드 목록입니다.
KeywordsPlus (SCOPUS) SCOPUS에서 자동으로 추출하거나 추가한 색인 키워드입니다.
Language 논문이 작성된 언어입니다. 대부분 English이며, 그 외 다양한 언어로 작성된 논문이 포함될 수 있습니다.
Publication Year 논문이 출판된 연도입니다.
Publication Date 논문의 정확한 출판 날짜입니다 (년-월-일 형식).
DOI Digital Object Identifier. 디지털 객체 식별자로, 논문을 고유하게 식별하는 영구적인 식별번호입니다. 이를 통해 논문의 온라인 위치를 찾을 수 있습니다.